ArticleDiscover oncology2025
Integrative transcriptomic and single-cell analysis reveals IL27RA as a key immune regulator and therapeutic indicator in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- The Carcinogenic Role of HMGB1 and NF-κB in Gastric Adenocarcinoma.Digestive diseases and sciences · 2026Article
- PINK1‑mediated mitophagy enhances breast cancer proliferation through metabolic reprogramming.Oncology reports · 2026Article
- Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy (Review).Oncology letters · 2026Review
- Article
- Identification of senescence-related genes as diagnostic biomarkers for gastric cancer using bioinformatics and machine learning.Discover oncology · 2026Article
- Mapping research trends in immune cell metabolic reprogramming in breast cancer: a parallel dual-database bibliometric study.Discover oncology · 2026Article
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2026Article
- Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.Discover oncology · 2026Article
- Targeting IL27RA Enhances Immunotherapy in Triple-Negative Breast Cancer by Modulating Tumor Cells and the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Analysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway.Scientific reports · 2026Article
- HOXB2 is a prognostic biomarker and correlated with immune infiltration in colorectal cancer and glioma.Discover oncology · 2026Article
- PLOD2 promotes proliferation, migration and invasion of colorectal cancer cells via PI3K-AKT-GSK3β signaling pathway.Scientific reports · 2026Article
- Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma.BMC cancer · 2026Article
- Comparison of the safety and efficacy of different neoadjuvant therapy cycles for locally advanced gastric cancer: a retrospective propensity score-matched cohort study.World journal of surgical oncology · 2026Article
- A novel ferroptosis- and endoplasmic reticulum stress-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer.Discover oncology · 2026Article
- DMBX1 expression in colon cancer and its impact on prognosis and the tumor microenvironment.BMC medical genomics · 2026Article
- Review
- Quercetin attenuates high glucose-induced VEGFA expression in ARPE-19 cells by inhibiting ROS generation, p38 MAPK phosphorylation, and NF-κB activation.Scientific reports · 2026Article
- Systematic pan-cancer analysis identifies PIK3R3 as a lipid metabolism and immune regulation prognostic biomarker.Open medicine (Warsaw, Poland) · 2026Article
- Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInterleukin-27 receptor alpha (IL27RA), a key subunit of the interleukin-27 receptor, plays an essential role in T cell-mediated immunity. However, its relevance in breast cancer and response to immunotherapy remains unexplored.
methodsWe integrated bulk and single-cell RNA sequencing data from TCGA, GEO, and scRNA-seq datasets to analyze IL27RA expression, prognosis, immune infiltration, and treatment response. TIDE and immune checkpoint-treated clinical cohorts were used to assess immunotherapy responsiveness. Chemotherapy sensitivity was predicted using GDSC data, and IL27RA protein expression was validated by Western blot.
resultsIL27RA was downregulated in breast cancer but high expression correlated with favorable survival. It was primarily expressed in T cells, particularly CD8⁺ subsets, and associated with enriched immune infiltration and elevated checkpoint gene expression. IL27RA high-expression patients showed lower TIDE scores, better outcomes in ICI-treated cohorts, and higher sensitivity to multiple chemotherapeutic agents.
conclusionIL27RA is a potential immune biomarker that reflects an inflamed tumor microenvironment and predicts benefit from immunotherapy and chemotherapy in breast cancer. These findings provide novel insights into immune-based stratification using single-cell transcriptomic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.